India's health biotech sector at a crossroads

Nature Biotechnology

Volumn 25, Issue 4, 2007, Pages 403-417

  Frew, Sarah E ^a   Rezaie, Rahim ^a   Sammut, Stephen M ^b,c   Ray, Monali ^a   Daar, Abdallah S ^a   Singer, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Burrill and Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INSUGEN; POLIOMYELITIS VACCINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERFERON; SHANFERON; STREPTOKINASE; UNCLASSIFIED DRUG; VACCINE;

BIOTECHNOLOGY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; ECONOMIC DEVELOPMENT; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEALTH SURVEY; IMMUNIZATION; INTERVIEW; POLITICS; PRIORITY JOURNAL; REVIEW;

BIOTECHNOLOGY; HUMANS; INDIA; INTERNATIONAL COOPERATION; PHARMACEUTICAL PREPARATIONS; PRIVATE SECTOR; PUBLIC HEALTH;

EID: 34147132345     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0407-403     Document Type: Review

References (16)

1. Kumar, N.K. et al. Indian biotechnology - rapidly evolving and industry led. Nat. Biotechnol. 22 Suppl, DC31-DC36 (2004).
2. Thorsteinsdóttir, H., Quach, U., Martin, D., Daar, A. & Singer, P. Health biotechnology innovation in developing countries. Nat. Biotechnol. 22 Suppl, DC1-DC52 (2004).
3. UNDP Commission on Private Sector and Development. Unleashing Entrepreneurship: Making Business Work for the Poor. United Nations Development Program, New York, (2004).
4. nd Edition (http://www.marketresearch.com, New York, 2005).
5. Palnitkar, U. Growth of Indian biotech companies, in the context of the international biotechnology industry. J. Commer. Biotechnol. 11, 146-154 (2005).
6. Dhawan, J., Gokhale, R.S. & Verma, I.M. Bioscience in India: times are changing. Cell 123, 743-745 (2005).
7. Mayor, S. Coming home. Nature 436, 488-489 (2005).
8. Wilkie, D. India wants to be your biotech source; a greater respect for intellectual property could boost India's ability to compete in 2005. The Scientist October 25, 2004) pp. 51-53.
9. De Rond, M. in Strategic Alliances as Social Facts: Business, Biotechnology, and Intellectual History (Cambridge University Press, Cambridge, UK, 2003).
10. Bleed, D. et al. Global Tuberculosis Control - Surveillance, Planning, Financing. India: Country Profile. (World Health Organization Geneva, 2006). http://www.who.int/tb/publications/global_report/2006/pdf/full_report.pdf
11. World Health Organization. Malaria Situation in SEAR Countries. (WHO, Geneva, 2004). http://www.searo.who.int/en/section10/section21/ section340_4021.htm
12. The Joint United Nations Program on HIV/AIDS and World Health Organization. Asia Fact Sheet: UNAIDS Epidemic Update. (2005). http://data.unaids.org/pub/GlobalReport/2006/200605-FS_Asia_en.pdf
13. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes. Diabetes Care 27, 1047-1053 (2004).
14. World Health Organization. Preventing Chronic Diseases; A Vital Investment (World Health Organization, Geneva, 2005). http://www.who.int/ chp/chronic_disease_report/en/index.html
15. Jayaraman, K.S. Biotech boom. Nature 436, 480-483 (2005).
16. BioSpectrum-ABLE. BioSpectrum-ABLE Survey 2005. in India Biotechnology Handbook 2006 (sponsored by Department of Biotechnology, Government of India, 2006).